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Abstract
Introduction: Encephalopathy is a rare disease caused by adverse effects of antibiotic drugs such as
metronidazole. The incidence of metronidazole-induced encephalopathy is unknown, although several previous
studies have addressed metronidazole neurotoxicity. Here, we report the case of a patient with reversible cerebellar
dysfunction on magnetic resonance imaging, induced by prolonged administration of metronidazole for the
treatment of infectious colitis.
Case presentation: A 71-year-old Asian man, admitted to our hospital with hematochezia, underwent Hartmann’s
operation for the treatment of colorectal cancer three years ago. He was diagnosed with an infectious colitis by
colonoscopy. After taking metronidazole, he showed drowsiness and slow response to verbal commands. Brain
magnetic resonance imaging showed obvious bilateral symmetric hyperintensities within his dentate nucleus, tectal
region of the cerebellum, and splenium of corpus callosum in T2-weighted images and fluid attenuated inversion
recovery images. Our patient’s clinical presentation and magnetic resonance images were thought to be most
consistent with metronidazole toxicity. Therefore, we discontinued metronidazole, and his cerebellar syndrome
resolved. Follow-up magnetic resonance imaging examinations showed complete resolution of previously noted
signal changes.
Conclusion: Metronidazole may produce neurologic side effects such as cerebellar syndrome, and encephalopathy
in rare cases. We show that metronidazole-induced encephalopathy can be reversed after cessation of the drug.
Consequently, careful consideration should be given to patients presenting with complaints of neurologic disorder
after the initiation of metronidazole therapy.
Introduction
Metronidazole is a commonly used antibiotic agent in
various conditions such as anaerobic bacterial infections,
protozoa infections (for example, giardiasis), Helicobac-
ter associated gastritis, and hepatoencephalopathy. Pre-
vious reports have demonstrated that metronidazole
toxicity may induce several neurologic side effects,
including peripheral neuropathy, ataxic gait, dysarthria,
convulsive seizures, and encephalopathy [1-4]. We
describe the case of a patient with metronidazole-
induced encephalopathy (MIE), with abnormalities
found following brain magnetic resonance imaging
(MRI), which had a succesful outcome after discontinu-
ance of metronidazole.
Case presentation
A 71-year-old Asian man, admitted with hematochezia,
had previously been diagnosed with type 2 diabetes and
underwent Hartmann’s operation for the treatment of
colorectal cancer three years ago. He was diagnosed
with an infectious colitis by colonoscopy. After taking
intravenous metronidazole for 14 days, he took oral
metronidazole for 14 days, and was discharged home
with oral metronidazole. Three days after discharge, he
presented to our emergency room with drowsiness and
slow response to verbal commands.
Neurological examination showed dysarthria, dysmetria
on finger-to-nose examination, and an ataxic wide-based
gait. Computed tomography (CT) performed on admis-
sion showed no evidence of acute hemorrhagic stroke
and laboratory analysis was unremarkable. Thus, the pre-
liminary diagnosis was cerebral infarction or metastatic
disease. Our patient underwent brain magnetic resonance
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symmetric hyperintensities within his dentate nucleus,
tectal region of the cerebellum, and splenium of cor-
pus callosum in T2-weighted images and fluid attenu-
ated inversion recovery (FLAIR) images (Figure 1).
The patient’s clinical presentation and MRI images
were thought to be most consistent with metronida-
zole toxicity. Therefore, we decided to discontinue
metronidazole, and the patient’s condition improved
slowly.
Three months after discontinuation of metronidazole,
a follow-up examination showed that our patient’sc e r e -
bellar syndrome had resolved. Follow-up MRI examina-
tion showed complete resolution of previously noted
signal changes (Figure 2).
Discussion
Metronidazole is available for treatment in anaerobic-
related infections but may produce a number of
neurologic side effects, such as cerebellar syndrome,
Figure 1 Initial MRI findings. A: T2-weighted image shows symmetrically increased signal intensities in the dentate nucleus of the cerebellum.
B: FLAIR image shows symmetrically increased signal intensities in the dentate nucleus of the cerebellum. C: Diffusion weighted image shows
no abnormality. D: Postgadolinium T1-weighted image shows no abnormality.
Kim et al. Journal of Medical Case Reports 2011, 5:63
http://www.jmedicalcasereports.com/content/5/1/63
Page 2 of 4encephalopathy, seizure, autonomic neuropathy, optic
neuropathy, and peripheral neuropathy [2,3]. The inci-
dence of MIE is unknown. The duration of treatment with
metronidazole before cerebellar symptoms manifest is
variable, and cumulative doses range from 25 g to 110 g
[5]. In our case, total doses of metronidazole were 45.5 g.
The pathogenesis of metronidazole neurotoxicity is
currently unknown and there are relatively few publica-
tions addressing the mechanism of metronidazole neu-
rotoxicity. It has been suggested that metabolites of
metronidazole may bind to RNA instead of DNA, possi-
bly inhibiting RNA protein synthesis, which could
potentially lead to axonal degeneration [6]. Another
proposed mechanism involves the modulation of the
inhibitory neurotransmitter gamma-aminobutyric acid
(GABA) receptor within the cerebellar and vestibular
systems [7].
Although the mechanism of metronidazole neuro-
toxicity remains unclear, most lesions induced by
metronidazole neurotoxicity may be wholly reversible.
The reversible changes associated with the acute toxic
effects of metronidazole are most likely due to axonal
swelling with increased water content rather than a
demyelinating process. A further suggested mechanism
involves vascular spasm that could produce mild rever-
sible localized ischemia [4]. MRI in patients with MIE
show that T2 hyperintense lesions in the cerebellar
dentate nuclei are most commonly involved. The
midbrain, dorsal pons, dorsal medulla, and corpus cal-
losum can also be affected. Uncommon locations
include the inferior olivary nucleus and the white mat-
ter of the cerebral hemispheres [4,8]. Lesions are
always symmetric and bilateral, which is a typical pat-
tern of metabolic encephalopathy. In each of the cases
we reviewed, including ours, there was symmetrical
increase of T2 signal intensity and absence of mass
effect and enhancement. Reversible changes have pre-
viously been observed through MRI in the brains of
patients with MIE [9].
In this case, our initial prediction - considering his
underlying disease - was either cerebrovascular accident
or metastatic cancer rather than drug-induced encepha-
lopathy. However, his clinical history and MRI findings
strongly suggested MIE. Our patient’ss y m p t o m s
resolved after cessation of the drug.
In the neurosurgical field, metronidazole is an alterna-
tive treatment for brain abscess in addition to surgical
excision. Thus, a neurosurgeon should be able to recog-
nize the adverse effects of metronidazole and a need for
early diagnosis of MIE.
Conclusions
Our case illustrates that metronidazole can cause rever-
sible neurotoxicity. Appropriate neurological examina-
tions, early diagnosis using MRI, and prompt cessation
of the medication will lead to a better prognosis. There-
fore, awareness of the potential neurological side effects
of metronidazole and an accurate clinical impression of
the attending physician is very important in metronida-
zole-induced encephalopathy.
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